SLU-PP-332 FDA Approval Status and 2026 Regulatory Outlook

The Short Answer

As of 2026, SLU-PP-332 is not FDA-approved for any indication. It is not present on the FDA 503A bulk drug substances list, and it is not a component of any currently approved or commercially available pharmaceutical product in the United States. Compounding through licensed 503A or 503B pharmacies is therefore not an established access pathway.

For physicians whose patients are asking about clinical availability, the simple and accurate response is that SLU-PP-332 is a preclinical research compound with no sanctioned clinical use at this time.

 

What the Current Regulatory Status Means in Practice

Not FDA-approved. No IND, NDA, or BLA for a completed clinical indication. The compound has not crossed the regulatory threshold for prescription pharmaceutical use.

Not on the 503A bulk drug substances list. The 503A list governs what substances compounding pharmacies can legally use as starting materials for compounded preparations in the absence of an FDA-approved product. SLU-PP-332 is not on this list.

Not on the interim 503A category review lists. The Pharmacy Compounding Advisory Committee (PCAC) periodically reviews substances for potential addition. As of the April 2026 regulatory cycle, SLU-PP-332 is not among the substances under active consideration.

Not WADA-banned (as a named entity) — but substance class is covered. The World Anti-Doping Agency prohibited list applies to relevant receptor-agonist classes. Compounds in the exercise-mimetic mechanistic space are of interest to anti-doping authorities and athletes should assume that use would be prohibited regardless of specific listing status.

 

Why Patients Encounter SLU-PP-332 at All

Despite the absence of clinical access, SLU-PP-332 has surface area in patient and clinician conversation because:

• Research-grade material circulates through channels intended for laboratory use
• Longevity and biohacker communities have publicized the preclinical findings
• Peptide-clinical communities have included it in broader discussions of metabolic compounds
• The PR value of “exercise in a pill” framing has amplified coverage beyond what the data currently support

The gap between media salience and actual clinical availability is the defining feature of the current moment for this compound.

 

What Would Change the Regulatory Picture

Several developments would materially alter the status:

• Completion of a well-characterized phase 1 human trial with a published safety/PK dataset
• IND activation supporting a defined clinical development path
• Phase 2 efficacy data in a specific indication (likely metabolic disease or exercise-limited conditions)
• Commercial sponsor emerging from an academic or biotech starting position

None of these would by themselves place SLU-PP-332 on the 503A bulk drug substances list — that pathway requires a separate regulatory process under section 503A of the Federal Food, Drug, and Cosmetic Act.

 

The Counseling Point for Clinicians

Patients who approach their physician with questions about obtaining SLU-PP-332 should be given an honest answer grounded in the current regulatory facts: it is not available through legitimate clinical or compounding channels, and sources outside those channels are not an appropriate foundation for patient care. A physician’s role in that conversation is to:

• Explain why the compound is not clinically available
• Address the underlying question the patient is trying to solve (often metabolic optimization, weight management, or exercise tolerance)
• Offer evidence-based alternatives that can be implemented today

 

Key Takeaways

• SLU-PP-332 is not FDA-approved.
• It is not on the 503A bulk drug substances list.
• It is not accessible through legitimate compounding channels.
• Patient interest is driven by preclinical data and popular media, not clinical evidence.
• Clinicians should redirect patient questions toward evidence-based alternatives while monitoring the regulatory status as it evolves.

 

Frequently Asked Questions

Is SLU-PP-332 FDA-approved?

No. It is not approved for any indication.

Can I get SLU-PP-332 from a compounding pharmacy?

Legitimate 503A compounding pharmacies cannot use SLU-PP-332 as a starting material because it is not on the 503A bulk drug substances list.

Is SLU-PP-332 banned by WADA?

WADA covers relevant receptor-agonist classes. Athletes should assume that use would be prohibited and should consult official WADA resources for definitive guidance.

When might SLU-PP-332 become available?

There is no reliable timeline. A plausible minimum would be several years from phase 1 initiation to any commercial indication, with substantial probability of the program not reaching approval.

Contact Us